eMolecules acquires Synple Chem AG
"We are thrilled to welcome the highly reputable and talented Synple team into eMolecules"
eMolecules, Inc. announced that it has acquired Synple Chem AG ("Synple"). Synple was founded in 2016 as a Spin-off from ETH Zürich. Synple specializes in automated chemical synthesis systems and solutions for small molecules drug discovery customers. With Synple's virtual compound library, which provides access to more than 7 trillion tractable compounds, combined with eMolecules' eXplore library of more than 4 trillion compounds, eMolecules now offers the world's most diverse selection of virtual compounds.
Symbolic image
Computer-generated image
Headquartered near Zurich, Synple serves premier pharma and biotech customers in the United States and in Europe. The acquisition strategically expands eMolecules' product and service portfolio to include automation solutions and enhances its one-stop-shop offering for drug discovery customers.
Researchers can quickly and efficiently search for and obtain compounds from hundreds of specialty chemical suppliers with over 100 million in-stock SKUs, while simultaneously searching across their own proprietary libraries and now also trillions of virtual compounds via eMolecules' and Synple's virtual libraries.
"We are thrilled to welcome the highly reputable and talented Synple team into eMolecules," said Dr. Niko Gubernator, CEO and President of eMolecules. "As a combined company, we are poised to deepen and broaden our relationships with research organizations. Our customers have expressed the need for a true, global, end-to-end partner to support efficient compound procurement, management and automation across regionally distributed chemistry groups. We look forward to capitalizing on opportunities to expand our offerings and innovate for our customers."
"We are excited to join forces with eMolecules, a company that shares our vision of revolutionizing the way researchers access chemical compounds and the chemical space," said Dr. Benedikt Wanner, CEO of Synple. "By integrating Synple's automated synthesis technology and extensive virtual compound library into eMolecules' unparalleled search-and-fulfillment platform, we are uniquely positioned to empower drug discovery teams with the tools they need to accelerate innovation and their discovery faster than ever before."
"The transaction perfectly aligns to eMolecules' business model and continued investments in creating a global one-stop shop for highly differentiated specialty chemistry services and solutions," said Sriram Venkataraman, Partner at Avista Healthcare Partners, eMolecules' primary investor. "With Synple's massive virtual library and highly efficient automated synthesis platform, the combination represents a significant step forward in eMolecules' growth story."
eMolecules is a portfolio company of Avista Healthcare Partners, a leading private equity firm focused exclusively on healthcare.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
